Want to see HK:1228 full AI Analyst Report?
Top Page
CANbridge Pharmaceuticals Inc.
(1228)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$2.00
▼(-20.63% Downside)
Action:Reiterated
Date:07/01/26
The score is held down primarily by weak financial performance (negative equity, ongoing cash burn, and persistent operating losses), with only partial offset from improving trends (reduced debt and improved cash burn in 2025). Technicals are supportive with the price above key moving averages, but valuation is a headwind given the high P/E and lack of dividend support.
Positive Factors
Rare-disease / specialty focus
A strategic focus on rare and underserved diseases creates structural advantages: smaller, less crowded markets, pricing power for specialty therapies, and greater partner interest for in-licensing/out-licensing. This model reduces discovery risk and supports durable revenue per approved asset once commercial traction is achieved.
Negative Factors
Negative shareholders' equity
Persistent negative shareholders' equity is a structural weakness that constrains financial flexibility, limits borrowing capacity, and can raise counterparty and investor concerns. It increases reliance on external financing and raises the risk of dilutive capital raises or covenant pressure over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Rare-disease / specialty focus
A strategic focus on rare and underserved diseases creates structural advantages: smaller, less crowded markets, pricing power for specialty therapies, and greater partner interest for in-licensing/out-licensing. This model reduces discovery risk and supports durable revenue per approved asset once commercial traction is achieved.
Read all positive factors
CANbridge Pharmaceuticals Inc. (1228) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.18B
Dividend YieldN/A
Average Volume (3M)5.03M
Price to Earnings (P/E)36.5
Beta (1Y)1.12
Revenue Growth-41.19%
EPS GrowthN/A
CountryHK
Employees67
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding597,443,360
10 Day Avg. Volume2,153,700
30 Day Avg. Volume5,027,972
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)-3.32
Price to Sales (P/S)22.72
P/FCF Ratio-29.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.67
Revenue Forecast (FY)HK$299.65M
CANbridge Pharmaceuticals Inc. Business Overview & Revenue Model
Company Description
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzym...
How the Company Makes Money
CANbridge’s revenue model is centered on monetizing a portfolio of specialty/rare-disease therapeutics through commercialization and partnering. Key potential revenue streams include: (1) Product sales revenue from commercialized medicines (where ...
CANbridge Pharmaceuticals Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.56M | 49.98M | 85.10M | 102.87M | 78.97M | 31.16M |
| Gross Profit | 40.29M | 36.55M | 54.30M | 64.16M | 48.89M | 18.78M |
| EBITDA | -150.16M | -78.98M | -328.69M | -341.43M | -454.63M | -1.06B |
| Net Income | -136.11M | 14.82M | -442.62M | -378.84M | -483.48M | -1.08B |
Balance Sheet | ||||||
| Total Assets | 105.50M | 165.46M | 116.81M | 395.36M | 702.04M | 892.52M |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 66.65M | 10.50M | 137.49M | 451.16M | 745.82M |
| Total Debt | 34.97M | 16.09M | 135.78M | 141.93M | 155.28M | 52.10M |
| Total Liabilities | 514.58M | 507.36M | 591.30M | 435.15M | 393.49M | 199.13M |
| Stockholders Equity | -409.08M | -341.90M | -474.49M | -39.79M | 308.56M | 693.39M |
Cash Flow | ||||||
| Free Cash Flow | -23.02M | -38.22M | -122.50M | -319.09M | -315.76M | -592.40M |
| Operating Cash Flow | -22.92M | -38.21M | -122.39M | -278.23M | -280.98M | -587.07M |
| Investing Cash Flow | 931.00K | 1.23M | 13.93M | -26.86M | -34.79M | 126.09M |
| Financing Cash Flow | -31.16M | 92.47M | -18.57M | -28.02M | -20.70M | 854.31M |
CANbridge Pharmaceuticals Inc. Technical Analysis
Negative
2.52
Price Trends
2.09
Negative
2.41
Negative
2.35
Negative
Market Momentum
<0.01
Negative
47.87
Neutral
42.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1228, the sentiment is Negative. The current price of 2.52 is above the 20-day moving average (MA) of 2.01, above the 50-day MA of 2.09, and above the 200-day MA of 2.35, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 47.87 is Neutral, neither overbought nor oversold. The STOCH value of 42.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1228.
CANbridge Pharmaceuticals Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$36.36B | 39.11 | 23.99% | ― | 16.65% | 0.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$1.18B | 36.51 | -3.63% | ― | -41.19% | ― | |
46 Neutral | HK$7.43B | -58.77 | -6.26% | ― | -11.65% | -169.40% | |
45 Neutral | HK$4.09B | -22.96 | -17.64% | ― | -65.87% | 6.71% | |
44 Neutral | HK$9.57B | -72.73 | -11.21% | ― | 219.26% | 87.63% | |
42 Neutral | HK$38.50B | -55.45 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:1228
CANbridge Pharmaceuticals Inc.
1.98
1.55
360.47%
HK:9966
Alphamab Oncology
7.63
1.34
21.30%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
5.20
0.47
9.94%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
18.83
-5.07
-21.21%
HK:2171
CARsgen Therapeutics Holdings Ltd.
15.88
-5.62
-26.14%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
66.70
11.65
21.16%
CANbridge Pharmaceuticals Inc. Corporate Events
CANbridge Shareholders Approve All Resolutions at 2026 AGM
Jun 23, 2026
Shareholders of CANbridge Pharmaceuticals Inc. approved all resolutions at the company’s annual general meeting held on June 23, 2026, with each item passed by poll as an ordinary resolution. The agenda included adoption of the 2025 audited ...
CANbridge Sets New Connected Service Deals With WuXi Biologics and Baheal Medical
Jun 16, 2026
CANbridge Pharmaceuticals has entered into a service procurement framework agreement with WuXi Biologics, effective from June 16, 2026 to December 31, 2028, under which WuXi Biologics, a 16.21% shareholder, will continue to provide biologics-relat...
CANbridge Sets 2026 Virtual AGM, Seeks Share Issuance Mandate Renewal
Jun 2, 2026
CANbridge Pharmaceuticals Inc. has called a virtual annual general meeting for June 23, 2026, where shareholders will review the audited consolidated financial statements and directors’ and auditor’s reports for the year ended December...
CANbridge Ties CEO Equity Award to Licensing Milestones and Sales Growth
Apr 12, 2026
CANbridge Pharmaceuticals has proposed granting 6,372,574 share options and an equal number of restricted share units to its chairman and chief executive officer, Dr. Xue, under its post-IPO incentive schemes, pending independent shareholder appro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.